TIAA CREF Investment Management’s ImmunityBio IBRX Stock Holding History

TIAA CREF Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$186K	Buy	117,938 +68,686	+139%	+$86.2K	﹤0.01%	2896
2018 Q4	$57K	Hold	49,252	–	–	﹤0.01%	2993
2018 Q3	$182K	Sell	49,252 -17,695	-26%	-$55.9K	﹤0.01%	2999
2018 Q2	$205K	Sell	66,947 -22,505	-25%	-$83.3K	﹤0.01%	3031
2018 Q1	$348K	Buy	89,452 +11,942	+15%	+$52.4K	﹤0.01%	2875
2017 Q4	$348K	Sell	77,510 -5,244	-6%	-$24.8K	﹤0.01%	2904
2017 Q3	$453K	Buy	82,754 +1,339	+2%	+$8.25K	﹤0.01%	2866
2017 Q2	$618K	Buy	81,415 +29,704	+57%	+$128K	﹤0.01%	2763
2017 Q1	$184K	Sell	51,711 -1,439	-3%	-$7.11K	﹤0.01%	3005
2016 Q4	$304K	Buy	53,150 +4,630	+10%	+$30.9K	﹤0.01%	2975
2016 Q3	$377	Buy	48,520 +1,568	+3%	+$11.7K	﹤0.01%	2950
2016 Q2	$292K	Buy	46,952 +25,729	+121%	+$200K	﹤0.01%	3043
2016 Q1	$174K	Buy	21,223 +2,410	+13%	+$22.7K	﹤0.01%	3000
2015 Q4	$326K	Buy	18,813 +12,979	+222%	+$193K	﹤0.01%	3000
2015 Q3	$67K	Buy	+5,834	New	+$127K	﹤0.01%	3085

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TIAA CREF Investment Management's IBRX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its ImmunityBio (IBRX) stake by 139% in Q1 2019, buying an estimated $86.2K and bringing the position to 117,938 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

TIAA CREF Investment Management first reported a position in IBRX in Q3 2015 and has held it in 15 quarters since. The position peaked at $618K in Q2 2017. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

TIAA CREF Investment Management held 117,938 shares of ImmunityBio worth $186K as of Q1 2019.
TIAA CREF Investment Management bought 68,686 ImmunityBio shares in Q1 2019, an estimated $86.2K.
ImmunityBio made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2896 holding.
TIAA CREF Investment Management first reported a position in ImmunityBio in Q3 2015 and has held it in 15 quarters since.
TIAA CREF Investment Management's ImmunityBio position peaked at $618K in Q2 2017.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.